Amanda L. Gill

Amanda L. Gill

Auto-generated profile, based on publicly available information

Amanda L. Gill

Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2023 in Science Immunology
Verified
Journal Article
Closed access
AGAmanda L. Gill
Amanda L. Gill
PWPeter H. Wang
Peter H. Wang
JLJudong Lee
Judong Lee
WHWilliam H. Hudson
William H. Hudson
SASatomi Ando
Satomi Ando
RARafi Ahmed
Rafi Ahmed
PD-1 + TCF-1 + stem-like CD8 T cells act as critical resource cells for maintaining T cell immunity in chronic viral infections and cancer. In addition, they provide the proliferative burst of effector CD8 T cells after programmed death protein 1 (PD-1)–directed immunotherapy. However, it is not known whether checkpoint blockade diminishes the number of these stem-like progenitor cells as effector cell differentiation increases. To investigate this, we used the mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection. Treatment of chronically infected mice with either αPD-1 or αPD-L1 antibody not only increased effector cell differentiation from the virus-specific stem-like CD8 T cells but also increased their proliferation so their numbers were maintained. The increased self-renewal of LCMV-specific stem-like CD8 T cells was mTOR dependent. We used microscopy to understand the division of these progenitor cells and found that after PD-1 blockade, an individual dividing cell could give rise to a differentiated TCF-1 − daughter cell alongside a self-renewing TCF-1 + sister cell. This asymmetric division helped to preserve the number of stem-like cells. Moreover, we found that the PD-1 + TCF-1 + stem-like CD8 T cells retained their transcriptional program and their in vivo functionality in terms of responding to viral infection and to repeat PD-1 blockade. Together, our results demonstrate that PD-1 blockade does not deplete the stem-like population despite increasing effector differentiation. These findings have implications for PD-1–directed immunotherapy in humans.

8 January 2025 in Nature
Verified
Journal Article
Closed access
PDF file
DMDaniel T. McManus
Daniel T. McManus
RVRajesh M. Valanparambil
Rajesh M. Valanparambil
CMChristopher B. Medina
Christopher B. Medina
CSChristopher Scharer
Christopher Scharer
DMDonald J. McGuire
Donald J. McGuire
RARafi Ahmed
Rafi Ahmed

31 January 2023 in Journal of Virology
Verified
Journal Article
Closed access
AGAmanda L Gill
Amanda L Gill
WHWilliam H Hudson
William H Hudson
RVRajesh M Valanparambil
Rajesh M Valanparambil
EAEunseon Ahn
Eunseon Ahn
DMDonald J McGuire
Donald J McGuire
RARafi Ahmed
Rafi Ahmed
CD8 T cells play a critical role in viral immunity and it is important to understand how memory cells are formed and what processes lead to their long-term maintenance. Here, we use a mouse model of acute infection to perform an in-depth, longitudinal analysis of memory CD8 T cell differentiation, examining the phenotype and location of memory cells out to 1 year postinfection.

12 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
RARafi Ahmed
Rafi Ahmed
DMDaniel McManus
Daniel McManus
RVRajesh Valanparambil
Rajesh Valanparambil
CMChristopher Medina
Christopher Medina
YHYinghong Hu
Yinghong Hu
HKHaydn Kissick
Haydn Kissick
Virus specific PD-1+ TCF-1+ TOX+ stem-like CD8+ T cells are essential for maintaining T cell responses during chronic infection and are also critical for PD-1 directed immunotherapy. In this study we have used the mouse model of chronic LCMV infection to examine when these virus specific stem-like CD8+ T cells are generated during the course of chronic infection and what is the role of antigen in maintaining the stem-like program. We found that these stem-like CD8+ T cells are generated early (day 5) during chronic infection and that antigen is essential for maintaining their stem-like program. This early generation of stem-like CD8+ T cells suggested that the fate commitment to this cell population was agnostic to the eventual outcome of infection and the immune system prepares a priori for a potential chronic infection. Indeed, we found that an identical virus specific stem-cell like CD8+ T cell population was also generated during acute LCMV infection but these cells were lost once the virus was cleared. To determine the fate of these early PD-1+TCF-1+TOX+ stem-like CD8+ T cells that are generated during both acute and chronic LCMV infection we set up two reciprocal adoptive transfer experiments. In the first experiment we transferred day 5 stem-like CD8+ T cells from chronically infected into acutely infected mice and examined their differentiation after viral clearance. We found that these early stem-like CD8+ T cells downregulated canonical markers of the chronic stem-like CD8+ T cells and expressed markers (CD127 and CD62L) associated with central memory CD8+ T cells. In the second experiment, we transferred day 5 stem-like cells from acutely infected mice into chronically infected mice and found that these CD8+ T cells could function like resource cells after transfer into a chronic environment by generating effector CD8+ T cells in both lymphoid and non-lymphoid tissues while also maintaining the number of stem-like CD8+ T cells. These findings provide insight into the generation and maintenance of virus specific stem-like CD8+ T cells that play a critical role in chronic viral infection. In particular, our study highlights the early generation of stem-like CD8+ T cells and their ability to adapt to either an acute or chronic infection. These findings are of broad significance since these novel stem-like CD8+ T cells play an important role in not only viral infections but also in cancer and autoimmunity.